Effect of Xuezhikang Therapy on Expression of Pulmonary Hypertension Related miR-638 in Patients With Low HDL-C Levels
Open Access
- 20 December 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 764046
Abstract
Objective: Low plasma level of high-density lipoprotein cholesterol (HDL-C) associated with poor outcomes in several cardiovascular diseases, including pulmonary arterial hypertension (PAH). Regulation of miR-638 have been proved to be associated with PAH. The aim of this study was to evaluate the expression of miR-638 after Xuezhikang (XZK) therapy in patients with low HDL-C.Methods: Plasma levels of miR-638 were quantified by real-time polymerase chain reactions in 20 patients with PAH and 30 healthy controls. A total of 40 subjects with low HDL-C were assigned to receive an XZK therapy for 6 months. The miR-638 expression profiles were detected in PAH patients, XZK-treated subjects and lovastatin treated pulmonary arterial smooth muscle cells (PA-SMCs).Results: The relative expression level of miR-638 in the plasma was lower in the PAH patients than that in the controls (p < 0.001). An increase of 11.2% from baseline in the HDL-C level was found after XZK therapy (p < 0.001). The relative expression of miR-638 was increased after XZK treatment (p < 0.01). The changes of miR-638 were inversely associated with baseline HDL-C levels. A significantly reduction in miR-638 expression were found in PDGF-BB-treated hPA-SMCs compared to the control cells, and the pre-treatment of the cells with lovastatin significantly re-gain the expression levels in miR-638.Conclusion: In patients with low HDL-C levels, XZK therapy raised the expression of miR-638, suggesting that the potential therapeutic effect of XZK in PAH patients with low serum HDL-C levels deserves further exploration.Keywords
This publication has 31 references indexed in Scilit:
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Association of polymorphisms in the MAFB gene and the risk of coronary artery disease and ischemic stroke: a case–control studyLipids in Health and Disease, 2015
- Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patientsBMJ, 2014
- Short- and long-term effects of Xuezhikang (血脂康), an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levelsChinese Journal of Integrative Medicine, 2014
- Xuezhikang Therapy Increases miR-33 Expression in Patients with Low HDL-C LevelsDisease Markers, 2014
- MicroRNA-638 is highly expressed in human vascular smooth muscle cells and inhibits PDGF-BB-induced cell proliferation and migration through targeting orphan nuclear receptor NOR1Cardiovascular Research, 2013
- Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglyceridesNature, 2011
- Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosisJournal of Clinical Investigation, 2011
- MiR-33 Contributes to the Regulation of Cholesterol HomeostasisScience, 2010
- Impact of Xuezhikang on coronary events in hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS)Annals of Medicine, 2010